Recipharm moves into lyophilisation

Recipharm AB has today announced the purchase of the lyophilisation facilities of Inotech Labor AG in Basel Switzerland. A newly formed company, Recipharm AG, will now operate the facility.

The capability to provide lyophilisation adds an important niche component to Recipharm’s combined contract manufacturing and drug development and formulation expertise. As the facility has the capability to handle batch sizes of up to 250 litres of drug substance at a time, it can prepare materials for clinical trials and support small-scale commercial drug production.

Thomas Eldered, CEO and managing director, Recipharm, commented: “We are very pleased to have acquired this modern lyophilisation facility from Inotech Labor as is right in the heart of Switzerland’s growing biopharmaceuticals industry where there is strong demand for this specialist technique. Furthermore, we are inheriting a strong order book, which creates and ideal platform for us to market our new services to existing clients. We also plan to offer Recipharm’s full suite of manufacturing and development services to current users of the Basel facility.”

Mr Eldered added, “Bringing lyophilisation into our service offering forms an integral part of our strategy to become one of the pre-eminent drug development and formulation companies in Europe. It also represents an important step in our strategic drive to expand into the realm of biologicals. Being profitable and cash positive enabled us to move fast during the bidding process and to emerge as Inotech Labor’s preferred purchaser.

The filling equipment at Inotech Labor Ag’s plant in Basel was only updated just over a year ago, and Recipharm is retaining the existing staff to manage and run the operation.